UNITY Biotechnology will present ASPIRE Phase 2B study data on UBX1325 for diabetic macular edema at ARVO 2025.
Quiver AI Summary
UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual Meeting from May 4-8 in Salt Lake City. The presentation, titled "Safety and Efficacy of Senolytic Candidate UBX1325 for Diabetic Macular Edema," is scheduled for May 7, 2025. UNITY focuses on developing therapeutics aimed at slowing or reversing aging-related diseases and is particularly interested in age-related ophthalmic and neurologic conditions. The company cautioned that forward-looking statements made in the release may face uncertainties, including potential delays in clinical trials and funding challenges, stressing that actual results could differ significantly from expectations.
Potential Positives
- UNITY Biotechnology is presenting significant 36-week data from the ASPIRE Phase 2B study at a notable scientific meeting, which highlights the company's commitment to advancing research in age-related diseases.
- The presentation of UBX1325, a senolytic candidate for treating Diabetic Macular Edema, showcases UNITY's innovative approach to therapeutics in ophthalmology.
- Featuring a reputable presenter, Dr. Arshad M. Khanani, adds credibility and visibility to UNITY's research efforts and potential breakthrough in treatments.
- The upcoming presentation at the ARVO 2025 Annual Meeting offers an opportunity for UNITY to engage with industry leaders, potentially strengthening partnerships and attracting interest from investors and collaborators.
Potential Negatives
- Presence of substantial known and unknown risks related to drug development, including delays in clinical trials, which could affect the potential success of UNITY's therapies.
- Continuing uncertainties about UNITY's understanding of senescence biology that may impact its ability to develop effective therapeutics.
- Concern regarding the sufficiency of the company's cash runway, which could impact its operational capabilities and future projects.
FAQ
What is UNITY Biotechnology presenting at ARVO 2025?
UNITY is presenting 36-week data from the ASPIRE Phase 2B study on May 7, 2025.
Who is presenting UNITY's findings at the conference?
The presenter is Arshad M. Khanani, M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates.
What is the focus of UNITY's research?
UNITY focuses on developing therapeutics to slow, halt, or reverse diseases of aging, specifically in ophthalmologic and neurologic areas.
What are the potential benefits of UBX1325?
UBX1325 aims to provide transformative benefits for diabetic macular edema and other age-related diseases.
Where can more information about UNITY be found?
More information is available at UNITY’s website www.unitybiotechnology.com and on their social media platforms.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$UBX Insider Trading Activity
$UBX insiders have traded $UBX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $UBX stock by insiders over the last 6 months:
- ALEXANDER HIEU NGUYEN (CLO and Head of Ops) has made 0 purchases and 4 sales selling 20,119 shares for an estimated $21,212.
- ANIRVAN GHOSH (Chief Executive Officer) has made 0 purchases and 2 sales selling 1,074 shares for an estimated $1,988.
- LYNNE MARIE SULLIVAN (CFO & Head of Corp. Dev.) has made 0 purchases and 2 sales selling 289 shares for an estimated $516.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$UBX Hedge Fund Activity
We have seen 13 institutional investors add shares of $UBX stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) removed 79,354 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $77,481
- CITADEL ADVISORS LLC removed 69,210 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $67,576
- ALYESKA INVESTMENT GROUP, L.P. removed 60,930 shares (-6.6%) from their portfolio in Q4 2024, for an estimated $59,492
- BALLENTINE PARTNERS, LLC removed 57,046 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $55,699
- MORGAN STANLEY added 35,350 shares (+79.1%) to their portfolio in Q4 2024, for an estimated $34,515
- SEACREST WEALTH MANAGEMENT, LLC added 27,800 shares (+inf%) to their portfolio in Q1 2025, for an estimated $28,912
- BRIDGEWAY CAPITAL MANAGEMENT, LLC added 25,000 shares (+100.0%) to their portfolio in Q4 2024, for an estimated $24,410
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the Company will present 36-week data from the ASPIRE Phase 2B study at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held on May 4-8, 2025 in Salt Lake City, Utah.
ARVO 2025 Presentation Details:
Title:
Safety and Efficacy of Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b Trials
Presentation Number:
4014
Session:
Diabetic Macular Edema: Anti-VEGF
Date & Time:
Wednesday, May 7, 2025 at 11:00-11:15 a.m. MDT
Location:
Calvin L. Rampton Salt Palace Convention Center, Room 255ABC
Presenter:
Arshad M. Khanani, M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates
Additional presentation details are available on the ARVO 2025 website here .
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at
www.unitybiotechnology.com
or follow us on
X
and
LinkedIn
.
Forward-Looking Statements
This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, UNITY’s expectations regarding potential benefits, activity, effectiveness, safety, and market opportunity of UBX1325, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME and other ophthalmologic diseases, the expected timing of results of the clinical trial in UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including risks related to delay or disruption in clinical trials, risks relating to the uncertainties inherent in the drug development process, risks relating to UNITY’s understanding of senescence biology, and risks related to UNITY’s ability to raise funding. This press release also contains data from third parties relating to market size and treatment outcomes, which involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The Company may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general and the sufficiency of its cash runway, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on April 22, 2025, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.
Media Contact
Inizio Evoke Comms
Katherine Smith
[email protected]
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
[email protected]
